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A B S T R A C T
Purpose: Anonymised, routinely-collected healthcare data is increasingly being used for epilepsy
research. We validated algorithms using general practitioner (GP) primary healthcare records to identify
people with epilepsy from anonymised healthcare data within the Secure Anonymised Information
Linkage (SAIL) databank in Wales, UK.
Method: A reference population of 150 people with deﬁnite epilepsy and 150 people without epilepsy was
ascertained from hospital records and linked to records contained within SAIL (containing GP records for
2.4 million people). We used three different algorithms, using combinations of GP epilepsy diagnosis and
anti-epileptic drug (AED) prescription codes, to identify the reference population.
Results: Combining diagnosis and AED prescription codes had a sensitivity of 84% (95% ci 77–90) and
speciﬁcity of 98% (95–100) in identifying people with epilepsy; diagnosis codes alone had a sensitivity of
86% (80–91) and a speciﬁcity of 97% (92–99); and AED prescription codes alone achieved a sensitivity of
92% (70–83) and a speciﬁcity of 73% (65–80). Using AED codes only was more accurate in children
achieving a sensitivity of 88% (75–95) and speciﬁcity of 98% (88–100).
Conclusion: GP epilepsy diagnosis and AED prescription codes can be conﬁdently used to identify people
with epilepsy using anonymised healthcare records in Wales, UK.
© 2017 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Vast amounts of electronic, routinely-collected, medical and
related administrative data are generated in modern healthcare
systems. These data can be anonymised, linked and used for
healthcare research [1,2]. Large numbers of individuals can be
studied without having to speciﬁcally recruit individuals for
projects, which can be expensive, time-consuming and introduce
selection bias. Records can also be linked from a wide variety of
different sources, enabling a wide breadth of data to be analysed.
Routinely-collected data are increasingly being used for high
quality epilepsy studies [3–5].
Every individual in the United Kingdom (UK) is entitled to
register with a primary care General Practitioner (GP) and there is
evidence that almost everyone in the UK does register with a GP
[6]. GPs have a central role in providing primary care for people
with epilepsy through assessment, diagnosis, appropriate referral
to secondary and tertiary services, managing and prescribing
medications (including the vast majority of anti-epileptic drugs)
and creating and maintaining a centralised health care record. GPs
are the patient’s primary contact point for access to specialist
services. GP health records contain details of encounters with GPs
and other healthcare providers using Read codes.
Read codes are the current clinical terminology coding system
used in UK primary care systems to record symptoms, diagnosis
and prescriptions [7]. Read codes are hierarchical (with increasing
level of detail with increasing digits) e.g: F25 is used to record
epilepsy, F25A. is used for juvenile myoclonic epilepsy and F2540
for temporal lobe epilepsy.
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GP records have been used as the basis for epilepsy studies
within data repositories such as the clinical practice research
datalink (CPRD) and the Secure Anonymised Information Linkage
(SAIL) databank [4,8,9]. One of the limitations of using routinely-
collected data for epilepsy studies is the possibility of including
incorrectly recorded epilepsy diagnoses. In particular, it’s not
known how accurately epilepsy diagnoses made by hospital
specialists are recorded in GP records. Guidelines advise that
algorithms used for case ascertainment in routinely-collected data
studies are validated in each population studied [10]. The accuracy
of UK GP diagnosis codes has been validated for many diseases but,
to our knowledge, has only been partially validated for epilepsy
diagnosis [8,9,11]. In this study we speciﬁcally aimed to validate
the accuracy of algorithms using GP records to identify people with
epilepsy from anonymised, linked, routinely collected Welsh
healthcare data.
2. Method
In Wales, anonymised GP primary care electronic health records
are collated and linked with other data within the Secure
Anonymised Information Linkage (SAIL) databank [1,12]. We
searched the SAIL databank on 13th April 2016, at this time GP
records were available up to 31st December 2015 and there were
records for 73% of GP practices across Wales (approx. 2.4 million
people). GP records can be tracked over time, so that individual
patient’s records can be analysed longitudinally through multiple
GP practices. We used combinations of epilepsy diagnosis and anti-
epileptic drug (AED) prescription codes to create three epilepsy
case ascertainment algorithms.
We anonymously uploaded and linked a list of 150 individuals
with epilepsy and 150 individuals without epilepsy (reference
population) to existing SAIL records, using an established and
validated split-ﬁle approach [1,12]. We then compared the
performance of the three different epilepsy case ascertainment
algorithms within SAIL in identifying the reference population.
2.1. The reference population
The Swansea Epilepsy Database currently holds detailed clinical
information (including diagnosis, medications, imaging and EEG
results) for 960 patients seen by a clinician with a specialist
interest in epilepsy (neurologist or paediatric neurologist) treated
at Morriston Hospital, Swansea. 283 (29%) of these patients have
generalised epilepsy, 510 (53%) have focal epilepsy, 125 (13%) have
unclassiﬁable epilepsy and 42 (4%) have an uncertain diagnosis.
Between January and March 2015, we examined the database
and used a random number generator to select a sample of 100
adults (50 men and 50 women, who were over 16 at their last
consultation date) and 50 children (25 boys and 25 girls, who were
16 and under at their last consultation date) with a clinically
deﬁnite diagnosis of epilepsy from the database. The clinical record
and investigation results for each of these 150 individuals were
reviewed to conﬁrm a clinically deﬁnite diagnosis as per the
International League Against Epilepsy’s (ILAE) practical clinical
deﬁnition of epilepsy. These 150 individuals formed the reference
population of people with epilepsy.
To ascertain a control cohort, 300 patients were reviewed from
consecutive general neurology clinics run by neurologists and
paediatric neurologists. Their diagnosis was checked using clinic
letters stored in an electronic format on the hospital system.
Patients with a diagnosis of epilepsy were excluded. Using a
random number generator, we randomly selected a sample of 100
adults (50 men and 50 women, who were over 16 at their last
consultation date) and 50 children (25 boys and 25 girls, who were
16 and under at their last consultation date) from these 300
patients. These 150 individuals formed the reference population of
people without epilepsy.
We have previously estimated the sensitivity of an epilepsy case
ascertainment algorithm at 90% using GP diagnosis and AED
prescription [9]. Based on this, a sample size of 150 provides a 95%
conﬁdence interval of 10% for sensitivities (proportions) of 90%.
Table 1
Proportion of epilepsy cases (n = 145) and cases without epilepsy (n = 143) identiﬁed within SAIL using three different algorithms: A  Individuals with a primary care epilepsy
diagnosis code and at least two consecutive codes for prescription of an anti-epileptic drugs (AED); B  Individuals with an epilepsy diagnosis code only; C  Individuals with
at least two consecutive codes for prescription of an AED. See method section for deﬁnitions of positive predictive value, sensitivity, false positive rate, speciﬁcity and Youden’s
Index.*We included 145 (97 adults, 48 children) people with a hospital diagnosis of epilepsy and 143 (98 adults and 45 children) people without a hospital diagnosis of
epilepsy.
























Yes 122 2 98% (94–100) 84% (77–90) 1% (0–5) 99% (95–100) 0.83
No 23 141
Adults Yes 84 2 98% (92–100) 87% (78–93) 2% (0–7) 98% (93–100) 0.85
No 13 96
Children Yes 38 0 100% (91–100) 79% (65–90) 0% (0–8) 100% (92–100) 0.79
No 10 45




Yes 125 5 96% (91–99) 86% (80–91) 3% (1–8) 97% (92–99) 0.83
No 20 138
Adults Yes 85 2 98% (92–100) 88% (80–93) 2% (0–7) 98% (93–100) 0.86
No 12 96
Children Yes 40 3 93% (81–99) 83% (70–93) 7% (1–18) 93% (82–99) 0.76
No 8 42
C  AED only All
patients
Yes 133 39 77% (70–83) 92% (86–96) 27% (20–35) 73% (65–80) 0.65
No 12 104
Adults Yes 91 38 71% (63–78) 94% (87–98) 39% (30–49) 61% (51–71) 0.55
No 6 60
Children Yes 42 1 98% (94–100) 88% (75–95) 2% (0–12) 98% (88–100) 0.86
No 6 44
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2.2. Algorithm construction and assessment
We used three different algorithms to identify people with
epilepsy within SAIL: A) individuals with an epilepsy diagnosis
Read code and two prescriptions of the same AED within six
months; B) individuals with an epilepsy diagnosis Read code only
and C) individuals with two prescriptions of the same AED within
six months only.
We used version 2 Read codes. For diagnosis we used F25 and all
subcodes beginning with F25 as well as Read codes 1O30, 667B.,
and SC200. For AEDs we used dn and do (and all sub codes). For a
full list of Read codes used see Supporting information in Pickrell
et al 2015 [9].
2.3. Analysis and statistical tests
True positive (TP) cases had a hospital diagnosis of epilepsy and
were identiﬁed within SAIL as having epilepsy; true negative (TN)
cases did not have epilepsy as conﬁrmed by hospital records and
were not identiﬁed as having epilepsy within SAIL; false positive
(FP) cases did not have epilepsy as conﬁrmed by hospital records
and were identiﬁed as having epilepsy within SAIL; and false
negative (FN) cases had a hospital diagnosis of epilepsy and were
not identiﬁed as having epilepsy within SAIL. Positive predictive
value (PPV) was deﬁned as TP/(TP + FP); sensitivity TP/(TP + FN);
speciﬁcity TN/(TN + FP) and false positive rate (FPR) as FP/(FP + TN).
We calculated Youden’s index (J) using sensitivity + speciﬁcity–1,
as a measure of the accuracy of the algorithms. J ranges from 1 to
1 (J = 1 for a perfect test) [13]. Conﬁdence limits were calculated
using the exact binomial method. We used R version 3.0.1 to
perform the statistical analysis.
2.4. Ethical approval
This study was approved by SAIL’s independent Information
Governance Review Panel (project 387). The National Research
Ethics Service has conﬁrmed that SAIL projects using anonymised
data do not require speciﬁc NHS research ethics committee
approval.
3. Results
145 of the 150 reference cases with epilepsy (97%) and 143 of
the 150 reference cases without epilepsy (95%) were found to be
registered with a SAIL GP. The sensitivity, speciﬁcity, positive
predictive value, false positive rate and accuracy of each of the
three algorithms in identifying the reference cases are shown in
Table 1.
4. Discussion
Our results show that anonymised GP records can be used to
accurately identify patients with epilepsy diagnosed by a hospital
specialist in Wales. The best sensitivities achieved for all patients,
adults and children were 92%, 94% and 88% respectively. The
corresponding ﬁgures for speciﬁcity were 99%, 98% and 100%.
These ﬁgures compare well with sensitivities and speciﬁcities from
other similar epilepsy case deﬁnition validation studies in different
healthcare systems e.g. Australian, Italian and American studies
achieved sensitivities of 82–90% and speciﬁcities of 94–100% [14–
16]. We have previously used similar algorithms within the SAIL
databank to estimate the prevalence of epilepsy in Wales to be
0.77% (95% CI 0.76–0.79%) [9].
As with previous studies, algorithm A (diagnosis and AED code)
is the most speciﬁc (98–100%) given that it has the ‘narrowest’
criteria and algorithm C (AED only) is the most sensitive (88–94%)
with its ‘broader’ criteria. The large difference in speciﬁcity
between adults and children for algorithm C (61% c.f. 98%) can be
explained by the widespread use of AEDs for indications other than
epilepsy in adults (e.g. migraine, mood disorders and neuropathic
pain). AEDs are seldom prescribed for indications other than
epilepsy in children in the UK [8]. Our results suggest that using
criteria of AED prescription alone can be used to identify children
with epilepsy.
There was surprisingly little difference in performance between
algorithm A and B, Algorithm A (additional AED code) was more
speciﬁc than algorithm B and algorithm B was more sensitive but
their overall accuracy was comparable. GP diagnosis codes for
epilepsy therefore seem reliable in their own right. Although this is
expected, given that epilepsy diagnosis should be made in
secondary care in the UK and later transcribed into the primary
care record by GPs [17], to our knowledge this has not been
described before and is an important result for future research
involving GP epilepsy diagnosis codes.
Several factors may have improved UK GP epilepsy diagnosis
coding practice in recent years. The Quality Outcomes Framework
(QOF) for GPs was introduced in 2004 and provides ﬁnancial
incentives to GPs who achieve certain indicators. The current QOF
indicator for epilepsy includes a record of patients aged 18 or over
on drug treatment for epilepsy who have been seizure-free for the
last 12 months [18]. Previous QOF indicators have included an
indicator for maintaining a register of adults with epilepsy on anti-
epileptic drug treatment. Current UK guidelines for the diagnosis
and management of epilepsy advise structured management
systems and regular reviews within primary care which are likely
to encourage accurate epilepsy diagnosis coding [17,19].
We have used relatively small numbers in the reference
population in this study due to the resources needed to manually
check medical records and test results. We could not review the
anonymised data within SAIL to ascertain the reasons for the false
positive and false negative cases. We also did not stratify the non-
epilepsy cases into epilepsy mimics such as dissociative seizures
and acute symptomatic seizures which may have a higher
miscoding rate in GP records. At the time of analysis, 73% of the
Welsh population’s GP records were available within SAIL. This lack
of 100% coverage likely explains why a small number of the
reference cases with and without epilepsy were not ‘found’ in SAIL.
These results are speciﬁc to primary care records in Wales and
are not applicable to other healthcare systems or methods of
ascertaining epilepsy cases (for example hospital discharge
summaries). Other parts of the UK do have similar healthcare
systems and although the results may be generalizable to the
remainder of the UK further work needs to be done to prove this.
Currently there is no facility to include EEG and imaging data
within SAIL and so we could not include these in our ascertainment
algorithms. Additionally it is impossible to identify people with
epilepsy who do not attend their GP or have not been seen by a
hospital specialist.
Our reference epilepsy cohort was obtained from a secondary
care epilepsy database which may have provided a bias towards
people with more severe epilepsy. We selected a group of people
without epilepsy from patients who had attended general
neurology clinics as a control group. This group therefore does
not represent the ‘general’ population without epilepsy. However,
this group of patients may be considered as a ‘better test’ of
ascertainment algorithms as patients with other neurological
conditions may be more likely to be incorrectly coded as having
epilepsy than the general population. Conversely it is also possible
(although unlikely in our opinion) that neurologists would not
record a diagnosis of epilepsy in a general neurology clinic
appointment with a different focus (e.g. headache).
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The strengths of our study are that we have used a carefully
validated reference population with an epilepsy diagnosis from an
epilepsy specialist and without an epilepsy diagnosis to validate
algorithms within an established anonymised databank containing
extensive primary care records for at least 2.4 million people.
5. Conclusion
Using primary care epilepsy diagnosis codes is an accurate
method to identify patients with epilepsy within the SAIL
databank. Using AED prescription codes in addition to epilepsy
diagnosis codes increases the speciﬁcity and positive predictive
value by 2% at a cost of a 2% reduction in sensitivity. In children
using AED prescription codes alone is an accurate way to identify
epilepsy cases. These results are generalizable to other studies that
use UK primary care records for epilepsy case ascertainment and
can serve as a baseline measure of accuracy of case ascertainment
in such studies.
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